Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
This randomized phase II trial studies paclitaxel and carboplatin to see how well they work
compared with bleomycin sulfate, etoposide phosphate, and cisplatin in treating patients
with sex cord-ovarian stromal tumors that have spread to other places in the body and
usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent).
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not
yet known which chemotherapy regimen is more effective in treating sex cord-ovarian stromal
I. To assess the activity of paclitaxel and carboplatin with respect to progression free
survival (using bleomycin, etoposide, and cisplatin [BEP] as a reference) for newly
diagnosed advanced or recurrent chemonaive ovarian sex cord-stromal tumors.
I. To estimate the toxicity of paclitaxel and carboplatin, and bleomycin, etoposide, and
cisplatin in this patient population.
II. To estimate overall survival for paclitaxel and carboplatin relative to that of BEP.
III. To evaluate response rate in the subset of patients with measurable disease.
I. To collect fixed and/or frozen tumor tissue for future translational research studies.
II. To explore the utility of inhibin A and inhibin B as prognostic and predictive
biomarkers for ovarian sex cord-stromal tumors and to examine changes in these markers with
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 1
hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease
progression or unacceptable toxicity.
ARM II: Patients receive bleomycin sulfate IV on day 1 and etoposide phosphate* IV over 1
hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4
courses in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients who have received prior radiotherapy receive etoposide phosphate on days
After completion of study therapy, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then annually thereafter.
- Patients with histologically confirmed ovarian stromal tumor [granulosa cell tumor,
ganulosa cell-theca cell tumor, Sertoli-Leydig cell tumor (androblastoma), steroid
(lipid) cell tumor, gynandroblastoma, unclassified sex cord-stromal tumor, sex cord
tumor with annular tubules]
- Patients must have newly diagnosed, stage IIA - IV disease and must be entered within
eight weeks from surgery; they may have either measurable residual disease by
Response Evaluation Criteria In Solid Tumors (RECIST) criteria, or they may have no
measurable residual disease; OR, they must have biopsy-proven recurrent disease of
any stage and have never received cytotoxic chemotherapy
- Patients must have a Gynecologic Oncology Group (GOG) performance grade of 0, 1, or 2
- Patients of childbearing potential must have a negative serum pregnancy test and must
agree to practice an effective means of birth control
- Patients in the measureable disease cohort must have at least one "target lesion" to
be used to assess response on this protocol as defined by RECIST 1.1; tumors within a
previously irradiated field will be designated as "non-target" lesions unless
progression is documented or a biopsy is obtained to confirm persistence at least 90
days following completion of radiation therapy
- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl, equivalent to
Common Terminology Criteria for Adverse Events (CTCAE) grade 1
- Platelet greater than or equal to 100,000/mcl
- Creatinine no greater than the institutional upper limits of normal
- Bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (CTCAE grade 1)
- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST])
less than or equal to 3.0 x ULN (CTCAE grade 1)
- Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE grade 1)
- Neuropathy (sensory and motor) less than or equal to CTCAE grade 1
- No signs of clinically significant hearing loss
- Patients must have signed an approved informed consent and authorization permitting
release of personal health information
- Patients must have pulmonary function sufficient to receive bleomycin, with normal
lung expansion, absence of crackles on auscultation, and normal carbon monoxide
diffusion (DLCO), defined as greater than 80% predicted
- Patients with a history of hypersensitivity reactions to prior chemotherapy
administered for previous cancer diagnoses are eligible to participate in the study,
unless the hypersensitivity reaction consisted of anaphylaxis not amenable to
- Recovery from effects of recent surgery, radiotherapy, or chemotherapy
- Patients must be entered within 8 weeks after surgery performed for either 1)
initial diagnosis, staging, and/or cytoreduction, or 2) (if done) management of
recurrent disease in a chemonaive patient
- Any hormonal therapy directed at the malignant tumor must be discontinued at
least one week prior to registration; continuation of hormone replacement
therapy is permitted
- Patients who have received any prior cytotoxic chemotherapy or biologics for sex
cord-stromal tumors (SCSTs)
- Patients with apparent stage I disease who have not undergone a staging procedure
- Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer, are excluded if there is any evidence of other malignancy
being present within the last five years
- Woman who are pregnant or breastfeeding
- Patients with medical history or conditions not otherwise previously specified which
in the opinion of the investigator should exclude participation in this study; the
investigator can consult the study chair or study co-chairs for uncertainty in this